{
    "id": 26881,
    "fullName": "FLT3 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 positive indicates the presence of the FLT3 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "positive",
    "createDate": "08/18/2017",
    "updateDate": "07/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15002,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS62P1 inhibited growth of FLT3-positive acute myeloid leukemia cell lines in culture, and led to tumor growth inhibition and regression in patient-derived xenograft (PDX) models (Blood 2015 126(23):3806).",
            "molecularProfile": {
                "id": 28205,
                "profileName": "FLT3 positive"
            },
            "therapy": {
                "id": 7376,
                "therapyName": "AGS62P1",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12059,
                    "pubMedId": null,
                    "title": "AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts",
                    "url": "http://www.bloodjournal.org/content/126/23/3806?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20878,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20887,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 9494,
                "therapyName": "Midostaurin + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35376,
                "profileName": "CBL Y371del FLT3 pos"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20874,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20877,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20873,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20889,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 9494,
                "therapyName": "Midostaurin + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20893,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Quizartinib (AC220) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 9496,
                "therapyName": "PRT062607 + Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20897,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Nexavar (sorafenib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 9495,
                "therapyName": "PRT062607 + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20871,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture, and inhibited leukemic growth and prolonged survival in cell line xenograft models expressing FLT3 and CBL Y371H (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20890,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9494,
                "therapyName": "Midostaurin + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20866,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20905,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Crenolanib resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9497,
                "therapyName": "Crenolanib + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20892,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Quizartinib (AC220) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9496,
                "therapyName": "PRT062607 + Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Xospata (gilteritinib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9498,
                "therapyName": "Gilteritinib + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20907,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Entospletinib to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9499,
                "therapyName": "Entospletinib + Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20891,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Nexavar (sorafenib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 9495,
                "therapyName": "PRT062607 + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20867,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20870,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture, and inhibited leukemic growth and prolonged survival in cell line xenograft models expressing FLT3 and CBL Q365_E366insSK (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20865,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20868,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35378,
                "profileName": "CBL Q365_E366insSK FLT3 pos"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28205,
            "profileName": "FLT3 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35376,
            "profileName": "CBL Y371del FLT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35377,
            "profileName": "CBL Y371H FLT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35378,
            "profileName": "CBL Q365_E366insSK FLT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}